|
|
| | NJK14047 Basic information |
| Product Name: | NJK14047 | | Synonyms: | NJK14047;[1,1'-Biphenyl]-3-carboxamide, N-cyclopropyl-4'-[4-(2,3-dihydroxypropoxy)benzoyl]-6-methyl- | | CAS: | 1800576-41-3 | | MF: | C27H27NO5 | | MW: | 445.51 | | EINECS: | | | Product Categories: | | | Mol File: | 1800576-41-3.mol |  |
| | NJK14047 Chemical Properties |
| Boiling point | 685.9±55.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | pka | 12.99±0.20(Predicted) |
| | NJK14047 Usage And Synthesis |
| Uses | NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice[1]. | | in vivo | NJK14047 (2.5 mg/kg, i.p. for 7-21 days) ameliorates the collage-induced rehumatoid arthritis (CIA) in DBA-1J mice and Imiquimod (HY-B0180)-induced psoriasis (IIP) in BALB/c mice, suppresses the cytokines expressions of Th1, Th2, Th17 and Treg[1]. | Animal Model: | collage-induced rehumatoid arthritis in DBA-1J mice and imiquimod-induced psoriasis in BALB/c mice[1] | | Dosage: | 2.5 mg/kg | | Administration: | i.p. for 7 days for IIP-administrated BALB/c mice, i.p. for 21 days for CIA-administrated CBA-1J mice | | Result: | Ameliorated the collage-induced arthritis and CIA caused cartilage damage, inflammation, pannus formation, bone corrosion, and synovial hyperplasia.
Ameliorated the imiquimod induced psoriasis and IIP caused keratinocyte proliferation. |
| | References | [1] Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800. DOI:10.1016/j.intimp.2024.111800 |
| | NJK14047 Preparation Products And Raw materials |
|